Royalty Report: Drugs, Cancer, Disease – Collection: 245935

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology
  • Diagnostic
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245935

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, non-transferable (except as expressly authorized in this Agreement), royalty-bearing license, with the right to sublicense as qualified, under the Licensed Patents, Licensed Products Improvements to the extent Controlled by Licensor, and Licensed Know-How to use, develop, import, offer for sale, have sold and sell, the Licensed Products in the Territory, and a non-exclusive license thereunder to make and have made the Licensed Products worldwide, for all diagnostic, preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses (the “Field”).  Licensor also hereby grants Licensee a license to use the Dacogen Trademark as provided in this Agreement. Licensor reserves all rights not expressly granted herein, and no other rights shall be considered granted by Licensor by implication, estoppel, reliance, or otherwise. Notwithstanding anything to the contrary, no rights or licenses are granted by Licensor in this Agreement with respect to any active ingredient other than Decitabine or with respect to any product other than the Licensed Products.
License Property
Licensed Patents
6,613,753 – Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
6,982,253 – Liquid formulation of decitabine and use of the same
6,998,391 – Method for treating diseases associated with abnormal kinase activity
6,905,669 – Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

DACOGEN Trademark shall me mean the DACOGEN mark and accompanying logos associated with it.

Products shall mean (i) the product containing Decitabine which is the subject of Licensor’s NDA No. 21-790 as of the date of signing of this Agreement; and (ii) any other pharmaceutical product containing as an active ingredient Decitabine.

Decitabine shall mean the compound identified below, and all stereoisomers, salts and polymorphs of the compound identified below. Esters and acids of the compound identified below shall be included to the extent they constitute the same active ingredient as the compound identified below.

Decitabine
C8H12N404
Exact Mass 228.086
Mol. Wt. 228.205

Field of Use
The Field shall mean preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 25878

License Grant
Licensor hereby grants to Licensee an exclusive, non-transferable (except as expressly authorized in this Agreement), royalty-bearing license under the Licensed Patents and Licensed Know-How to develop, make, have made, use, import, offer for sale, and sell, the Licensed Products in the Territory. Licensee shall have the right to sublicense its rights in the Territory in the countries outside the U.S. to Licensees of the Licensed Product with Licensor’s written consent.
License Property
Licensor has acquired and is developing a compound known as Decitabine for the treatment of myelodysplastic syndrome (MDS). Dacogen is used as a treatment for Myelodysplastic Syndrome. (Myelodysplastic syndromes (MDS)– certain types of anemia or leukemia and certain types of blood or bone marrow cancer). Dacogen is a nucleoside analog. It works by blocking cell growth.

Dacogen is a treatment for patients with myelodysplastic syndromes (MDS).  Dacogen was approved by the FDA on 2nd May and is indicated for treatment of patients with MDS including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes. Licensor  is currently conducting a Phase III pivotal trial to evaluate Dacogen in patients with acute myeloid leukaemia (AML).

Licensed Patents
US/Foreign Patent
Number

Restoring Cancer-Suppressing functions to Neoplastic cells through DNA Hypomethylation
6,613,753
Restoring Cancer-Suppressing functions to Neoplastic cells through DNA Hypomethylation
10/613,222 (US 2004-0052864)
Restoring Cancer-Suppressing functions to Neoplastic cells through DNA Hypomethylation
10/686,047 (US 2004-0109846)
Restoring Cancer-Suppressing functions to Neoplastic cells through DNA Hypomethylation CT/US02/04135 (WO 02/067681)
Restoring Cancer-Suppressing functions to Neoplastic cells through DNA Hypomethylation
EP 02717415.0 1383379
Liquid Formulation of Decitabine and use of the same
PCT/US03/17293
(WO 03/103687)

Liquid Formulation of Decitabine and use of the same
10/071,849  (US 2003-0147813
Method for treating Chronic Myelogenous Leukemia
10/206,854  (US-2004-0127453)

Method for treating diseases associated with abnormal Kinase activity
10/206,854  (US-2004-0127453)

Method for treating diseases associated with abnormal Kinase activity

PCT/US03/03537
(WO 03/065995)

Compositions and methods for re-establishing Gene Transcription through inhibition of DNA Methylation and Histone Deacetylase
PCT/US02/12092
(WO 02/085400)
Pharmaceutical formulations targeting specific regions of the Gastrointestinal tract
60/423,179

Field of Use
Dacogen is our investigational anti-cancer therapeutic which is currently in clinical trials for the treatment of patients with myelodysplastic syndrome (“MDS”).

IPSCIO Record ID: 26488

License Grant
The Licensor grants to the Licensee worldwide rights to Azacitidine, Vidaza.
License Property
Vidaza is the subject of a completed and published Phase III study indicating its safety and efficacy in the treatment of myelodysplastic syndromes, or MDS, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.  The myelodysplastic syndromes are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to acute myelogenous leukemia or AML.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 3282

License Grant
Pursuant to the License Agreement, the Licensor, an University, granted the Licensee a worldwide exclusive License, for our Licensed field, with, inter alia, the right to subLicense, or assign the License in connection with a sale or transfer, including, until April 2020.
Field of Use
The Licensee is exclusive Licensee to the intellectual property in our Licensed field of multiple myeloma and related diseases as well as to prevention and management of treatment related consequences, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).

Licensee field is diagnostics in Multiple myeloma, or MM, a hematologic, or blood, cancer that develops in the bone marrow and specifically affects the plasma cells of the bone marrow.

The Licensee Licensed field includes applications to malignant and non-malignant human or animal pathologies, including but not limited to determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen. These uses, patent, and technology rights exclude using FISH, which is Licensed to a third party.

IPSCIO Record ID: 279359

License Grant
The Japanese Licensor grants an exclusive, even as to Licensor, right and license, with the right to grant sublicenses, in the field in the territory under Licensor Patent and Licensor Technical information to make, have made, develop, have developed, import, have imported, export, have exported, use, have used, offer to sell, sell, and have sold the Compound and/or the Product.
License Property
Licensor is the proprietor of certain patents and patent applications relating to the Compound and possesses technical information relating to the same.

Product shall mean any pharmaceutical preparation suitable for administration for human use containing the Compound as an active ingredient.

Compound shall mean the chemical compound [N-[3-(4,5-bipyrimidin-2-ylamino)-4-methylphenyl)-4-
{ [ (3S )-3-( dimethylamino) pyrrolidin- 1-yl) methyl}-3-(trifluoromethyl) benzamide], of which code name is designated as __-187.

Field of Use
NS-187 is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor. Bcr-Abl is commonly recognized as the primary molecular target in the treatment of CML.
Chronic myelogenous leukemia (CML) is a cancer that affects your blood cells and bone marrow — the soft part inside your bones where blood cells are made.

IPSCIO Record ID: 286043

License Grant
Licensor hereby grants to Licensee an exclusive sublicense under the Licensed Patents in the Field of Use to make and have made, manufacture and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use and have used and lease, sell and have sold Licensed  Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory and Licensor further grants to Licensee an exclusive sublicense  to use the Know-How to make and have made, manufacture  and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use the Know-How to use and hav  used and lease, sell and have sold Licensed Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory.
License Property
Licensed Patents means all of the intellectual property, granted to Licensor identified herein as Agreement  Compounds for the described Field of Use.

Patent Application # U.S.S.N. 60/073,603 entitled 'N,N-Bis(2-Hydroxybenzyl) Ethylenediamine-N,N-Diacetic Acid in Iron Chelating Theraphy'.

Agreement  Compounds means the monosodium salt of N,N-bis (2-hydroxybenzyl) ethylenediamine-N,N diacetic acid (hereinafter 'NaHBED' or 'HBED'), or any other mono-cation salt of HBED.

Intellectual property relates to develop and market a proprietary iron chelator.  Iron chelation therapy is the removal of excess iron from the body with special drugs.

Field of Use
Field of Use means iron overload conditions, including, but not limited to, Thalassemia, sickle-cell anemia, and myelodysplasia (but excluding neuro- degenerative disorders), but shall exclude uses of Agreement Compounds by a route of delivery other than subcutaneous or IM injection or IV infusion or transdermal.

Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.

Sickle cell anemia is an inherited form of anemia — a condition in which there aren't enough healthy red blood cells to carry adequate oxygen throughout your body.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 245950

License Grant
The Japanese Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field.
License Property
The Licensor is engaged in research and development of pharmaceutical product called TM-411, known as Tamibarotene.

The patents are regarding manufacturing method and Polymorphism and  combination use.

The Product shall mean any therapeutic or preventative pharmaceutical products containing the Compound as an ingredient.

The Compound shall mean the compound known as TM-411 (Tamibarotene), and any parts, analogs and derivatives thereof.

The trademark shall mean OSALEUKIN.

Field of Use
Field 1 shall mean the pharmaceutical prevention or treatment of acute promyelocytic leukemia (APL).

Field 2 shall mean the pharmaceutical prevention or treatment in human hematological malignancies, including but not limited to Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia (CMMoL), Chronic Myelocytic leukemia (CML) and Acute myelocytic leukemia (AML) and solid tumor indications except Hepatocelluar carcinoma (HCC). Field shall collectively mean Field 1 and Field 2.

IPSCIO Record ID: 352729

License Grant
For the Option Grant, Licensor grants Licensee the exclusive option to obtain the License.

Upon ’s Licensees exercise of the Option, Licensor grants a worldwide, irrevocable, exclusive license, with the right to sublicense, under the Licensors Patents, Know-How and interest in the Joint Inventions and Joint Patents, to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, and a worldwide, irrevocable, non-exclusive license, with the right to sublicense, under the Licensor Technical Information to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, collectively the License.

License Grant Upon Expiration of the Royalty Term. SGI hereby grants to GSK a worldwide, non-exclusive fully paid-up license, with the right to sublicense, under the SGI Know-How and SGI Technical Information to continue to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory upon Expiration in Entirety.

License Property
Licensor owns or possesses certain intellectual property with respect to the discovery and development of novel drug compounds, and believes that certain of these drug compounds may have the potential to be used therapeutically for the treatment of human cancer and other diseases.

CLIMBâ„¢ or CLIMB means that certain proprietary process, comprising hardware, software, bench chemistry, synthesis, analysis and testing used by Licensor for the purpose of the discovery, evaluation and development of new chemical entities.

Compound means any inhibitor of DNA methyltransferases, including DNA methyltransferase 1 (DNMT·1) and/or DNA methyltransferase 3 (DNMT-3) owned or Controlled by SGI, as well as  any pro-drugs of such compounds, any metabolites of such compounds having DNMT target activity, all stereoisomers of such compounds including salts, and any solvates or polymorphs of such compounds. Compound will not include Decitabine (S-aza-2 – deoxycytidine) and all stereoisomers, salts, polymorphs, esters and acids of Decitabine, Vidaza'•, or analogues of azacitidine. Compound will also not include polynucleosides or polynucleotides comprising at least one base of cytidine or its derivatives or analogues, including Decitabine.

Field of Use
The Field of use means the treatment, prevention, palliation or diagnosis of any disease or condition adverse to human or animal health.

Epigenetics refers to the regulation of genes with mechanisms other than changes to the underlying DNA sequence. Epigenetic processes are widely believed to play a central role in the development and progression of almost all cancers.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.